non-hodgkin's lymphoma

GS-9901 is a selective, orally active and potent PI3Kδ inhibitor (IC50: 1 nM) for the study of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

ARV-393 HCl is an orally active and potent PROTAC targeting BCL6 with antitumor activity for the study of non-Hodgkin's lymphoma.

ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL).

PNU-159682, a metabolite of anthracycline neomycin, is a DNA topoisomerase II inhibitor with excellent cytotoxicity.

TA 077, a nitrourea derivative, is commonly utilized in combination chemotherapy for the treatment of non-Hodgkin's lymphoma.

E3 Ligase Ligand-linker Conjugate 170 (Compound I) demonstrates antiproliferative activity in non-Hodgkin's lymphoma SU-DHL-4 cells, with an IC50 of less than 0.2 μM. This conjugate is composed of an E3 ligase ligand and a linker, making it suitable for use in PROTAC synthesis.

PRMT5-IN-48 (compound D3) is an orally active PRMT5 inhibitor with an IC50 of 20.7 nM, displaying antitumor activity. It effectively suppresses the growth of various cancer cells, induces apoptosis, and causes cell cycle arrest at the G0 G1 phase. PRMT5-IN-48 is applicable for research in non-Hodgkin's lymphoma (NHL).

SB-743921, a kinesin spindle protein (KSP) inhibitor, is used potentially for the treatment of non-Hodgkin's lymphoma (NHL).

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

Edatrexate (CGP 30694), also known as 10-Ethyl-10-deazaaminopterin, is an analog of Methotrexate that demonstrates antitumor activity against Methotrexate-resistant tumors. This antifolate antimetabolite is utilized in research related to non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and head and neck cancer [1] [2].

MRK003 is a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. MRK003 treatment induced caspase-dependent apoptosis and inhibited proliferation of MM and NHL cell lines and patient cells. Examination of signaling events after treatment showed time-dependent decrease in levels of the notch intracellular domain, Hes1 and c-Myc. MRK003 downregulated cyclin D1, Bcl-Xl and Xiap levels in NHL cells and p21, Bcl-2 and Bcl-Xl in MM cells. In addition, MRK003 caused an upregulation of pAkt, indicating crosstalk with the PI3K Akt pathway.

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody that displays anti-proliferative, apoptotic, and antibody-dependent cytotoxic effects in vitro and inhibits tumor growth in mice harboring human lymphomas, and is indicated for use in non-Hodgkin's lymphoma (NHL).

Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22. This naked antibody can be used to synthesize antibody-active molecule conjugators [Inotuzumab ozogamicin] and to study acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.Ulocplumab inhibits the migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation, induces apoptosis, and inhibits the growth and migration of cancer cells. Ulocplumab inhibits CXCL12-mediated chronic lymphocytic leukemia (CLL) cell migration in response to CXCR4 activation and induces apoptosis.)

Bectumomab (IMMU-LL 2), a humanized IgG2a monoclonal antibody (mAb) against human CD22 (antigen), serves as an anti-lymphoma agent. It is utilized in imaging procedures when combined with technetium 99 (Tc99m LL2 Fab), and employed in evaluating the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL). Additionally, Bectumomab is used to examine targeting efficacy prior to radioimmunotherapy (RIT) [1].

Imvotamab (IGM-2323), a CD20xCD3 bispecific IGM antibody featuring a dual-action mechanism, promotes physiological T cell activation to avoid both over-stimulation and immune function down-regulation. This compound is under development for addressing B-cell malignant tumors, including multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) [1] [2] [3] [4].

Loncastuximab (RB4v1.2), an anti-CD19 monoclonal antibody, exhibits antitumor properties and holds potential for treating non-Hodgkin's lymphoma (NHL), specifically diffuse large B-cell lymphoma (DLBCL) [1] [2].

Blinatumomab (AMG-10,MT-103) is a CD19 CD3 bispecific B-cell and T-cell binding antibody that directs T-cells to attack cancer cells by binding to both CD3 on T-cells and CD19 on cancer cells, and is used in acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

Iladatuzumab (MCDS0593A) is a monoclonal antibody targeting CD79B and is a naked antibody to the ADC compound Iladatuzumab vedotin, which has potential anticancer activity for the study of B-cell non-Hodgkin's lymphoma (B-NHL).

Detumomab, a mouse monoclonal antibody, targets human B-cell lymphoma and is utilized in research on various cancers, including non-Hodgkin's lymphoma (NHL).

Ibritumomab is a murine-derived anti-CD20 monoclonal antibody that kills tumor cells by forming free radicals in target cells and surrounding tissues.Ibritumomab is used in the study of non-Hodgkin's lymphoma.

L-Asparaginase (L-ASNase) (L-ASNase), a hydrolase that catalyzes the conversion of L-asparagine, used in acute lymphoblastic leukemia treatment.Asparaginase is an enzyme that is used as a medication. As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin.